Pancreatic gastrinoma

Summary

Pancreatic gastrinoma (MONDO:0024638) is a disease and 2 clinical trials. Top therapeutic interventions include bevacizumab and octreotide acetate. A subtype of pancreatic gastrin-producing neuroendocrine tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic gastrinoma
Mondo ID	MONDO:0024638
NCIT	C95596
UMLS	C5848106
MedGen	1849954
GARD	0025441
Is cancer (heuristic)	no

Also known as: pancreatic gastrinoma

Disease family

This is a subtype of pancreatic gastrin-producing neuroendocrine tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › gastrin-producing neuroendocrine tumor › pancreatic gastrin-producing neuroendocrine tumor › pancreatic gastrinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01229943	PHASE2	COMPLETED	Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
NCT03147768	PHASE1	COMPLETED	Laser Tissue Welding - Distal Pancreatectomy Sealing Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
OCTREOTIDE ACETATE	4	1